Disparities in Presentation at Time of Hepatocellular Carcinoma Diagnosis: A United States Safety-Net Collaborative Study.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
15
06
2020
accepted:
30
08
2020
pubmed:
26
9
2020
medline:
15
5
2021
entrez:
25
9
2020
Statut:
ppublish
Résumé
While hepatocellular carcinoma (HCC) is ideally diagnosed outpatient by screening at-risk patients, many are diagnosed in Emergency Departments (ED) due to undiagnosed liver disease and/or limited access-to-healthcare. This study aims to identify sociodemographic/clinical factors associated with being diagnosed with HCC in the ED to identify patients who may benefit from improved access-to-care. HCC patients diagnosed between 2012 and 2014 in the ED or an outpatient setting [Primary Care Physician (PCP) or hepatologist] were identified from the US Safety-Net Collaborative database and underwent retrospective chart-review. Multivariable regression identified predictors for an ED diagnosis. Among 1620 patients, median age was 60, 68% were diagnosed outpatient, and 32% were diagnosed in the ED. ED patients were more likely male, Black/Hispanic, uninsured, and presented with more decompensated liver disease, aggressive features, and advanced clinical stage. On multivariable regression, controlling for age, gender, race/ethnicity, poverty, insurance, and PCP/navigator access, predictors for ED diagnosis were male (odds ratio [OR] 1.6, 95% confidence interval [CI]: 1.1-2.2, p = 0.010), black (OR 1.7, 95% CI: 1.2-2.3, p = 0.002), Hispanic (OR 1.6, 95% CI: 1.1-2.6, p = 0.029), > 25% below poverty line (OR 1.4, 95% CI: 1.1-1.9, p = 0.019), uninsured (OR 3.9, 95% CI: 2.4-6.1, p < 0.001), and lack of PCP (OR 2.3, 95% CI: 1.5-3.6, p < 0.001) or navigator (OR 1.8, 95% CI: 1.3-2.5, p = 0.001). The sociodemographic/clinical profile of patients diagnosed with HCC in EDs differs significantly from those diagnosed outpatient. ED patients were more likely racial/ethnic minorities, uninsured, and had limited access to healthcare. This study highlights the importance of improved access-to-care in already vulnerable populations.
Sections du résumé
BACKGROUND
BACKGROUND
While hepatocellular carcinoma (HCC) is ideally diagnosed outpatient by screening at-risk patients, many are diagnosed in Emergency Departments (ED) due to undiagnosed liver disease and/or limited access-to-healthcare. This study aims to identify sociodemographic/clinical factors associated with being diagnosed with HCC in the ED to identify patients who may benefit from improved access-to-care.
METHODS
METHODS
HCC patients diagnosed between 2012 and 2014 in the ED or an outpatient setting [Primary Care Physician (PCP) or hepatologist] were identified from the US Safety-Net Collaborative database and underwent retrospective chart-review. Multivariable regression identified predictors for an ED diagnosis.
RESULTS
RESULTS
Among 1620 patients, median age was 60, 68% were diagnosed outpatient, and 32% were diagnosed in the ED. ED patients were more likely male, Black/Hispanic, uninsured, and presented with more decompensated liver disease, aggressive features, and advanced clinical stage. On multivariable regression, controlling for age, gender, race/ethnicity, poverty, insurance, and PCP/navigator access, predictors for ED diagnosis were male (odds ratio [OR] 1.6, 95% confidence interval [CI]: 1.1-2.2, p = 0.010), black (OR 1.7, 95% CI: 1.2-2.3, p = 0.002), Hispanic (OR 1.6, 95% CI: 1.1-2.6, p = 0.029), > 25% below poverty line (OR 1.4, 95% CI: 1.1-1.9, p = 0.019), uninsured (OR 3.9, 95% CI: 2.4-6.1, p < 0.001), and lack of PCP (OR 2.3, 95% CI: 1.5-3.6, p < 0.001) or navigator (OR 1.8, 95% CI: 1.3-2.5, p = 0.001).
CONCLUSIONS
CONCLUSIONS
The sociodemographic/clinical profile of patients diagnosed with HCC in EDs differs significantly from those diagnosed outpatient. ED patients were more likely racial/ethnic minorities, uninsured, and had limited access to healthcare. This study highlights the importance of improved access-to-care in already vulnerable populations.
Identifiants
pubmed: 32975686
doi: 10.1245/s10434-020-09156-4
pii: 10.1245/s10434-020-09156-4
pmc: PMC8099037
mid: NIHMS1695930
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1929-1936Subventions
Organisme : NCI NIH HHS
ID : T32 CA211034
Pays : United States
Organisme : NIH HHS
ID : T32CA211034
Pays : United States
Références
Hepatology. 2018 Aug;68(2):723-750
pubmed: 29624699
Gastroenterol Hepatol (N Y). 2019 Aug;15(8):423-430
pubmed: 31592079
J Viral Hepat. 2015 Sep;22(9):727-36
pubmed: 25581816
Dig Dis Sci. 2015 Jul;60(7):2183-9
pubmed: 25724166
J Cancer Res Clin Oncol. 2004 Jul;130(7):417-22
pubmed: 15042359
J Clin Gastroenterol. 2016 Mar;50(3):258-65
pubmed: 26352107
Front Oncol. 2018 Dec 03;8:579
pubmed: 30560091
J Natl Compr Canc Netw. 2015 May;13(5):543-9
pubmed: 25964640
World J Gastroenterol. 2019 Aug 7;25(29):3929-3940
pubmed: 31413528
J Environ Health Sci. 2019;5(2):90-92
pubmed: 32104722
Hepatol Commun. 2018 Sep 24;2(10):1274-1283
pubmed: 30288480
Clin Gastroenterol Hepatol. 2018 Jan;16(1):106-114.e5
pubmed: 28756056
Health Care Financ Rev. 1995 Fall;17(1):1-14
pubmed: 10153465
Am J Prev Med. 2018 Nov;55(5 Suppl 1):S40-S48
pubmed: 30670200
J Hepatocell Carcinoma. 2017 May 17;4:71-79
pubmed: 28553624
Top Antivir Med. 2013 Feb-Mar;21(1):15-9
pubmed: 23596274
Dig Dis Sci. 2019 Apr;64(4):910-917
pubmed: 30835028
Cancer. 2017 Apr 1;123(7):1219-1227
pubmed: 27859019
World J Gastroenterol. 2019 Apr 7;25(13):1550-1559
pubmed: 30983815
JAMA Oncol. 2017 Apr 1;3(4):456-463
pubmed: 27657493
J Carcinog. 2017 May 29;16:1
pubmed: 28694740
Clin Gastroenterol Hepatol. 2019 Mar;17(4):766-773
pubmed: 30056183
Cancer. 2018 Sep 1;124(17):3551-3559
pubmed: 30113700